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EDITORIAL
Relaxin and renal fibrosis
There is now widespread recognition that tubulointer- Experimentally, relaxin has been demonstrated to inhibit
stitial fibrosis is an important component in almost all pulmonary [4] and dermal fibrosis [5]. Recently, infusion
forms of progressive renal disease. This excessive accu- of 25 but not 100 mg/kg/day of relaxin over 24 weeks has
mulation of interstitial connective tissue, principally col- been shown to produce a reduction in skin thickening
lagen, has led to a search for therapeutic strategies di- in patients with scleroderma [6].
rected at this process. In this issue of Kidney International, Garber et al [2]
Indirect strategies aimed at inhibiting fibrosis by re- demonstrate that relaxin reduces renal fibrosis in an
ducing glomerular hyperfiltration and the effects of pro- acute experimental model of bromoethylamine-induced
teinuria on the tubule, through control of hypertension, papillary necrosis, where corticomedullary fibrosis is
angiotensin blockade, low protein diet, control of hyper- prominent [7]. They demonstrated that continuous sub-
glycaemia, and to a lesser extent control of hyperlipid- cutaneous infusion of relaxin commenced 1 week after
emia have been proved both experimentally and clini- injury dramatically reduced corticomedullary scarring.
cally. A more direct strategy would be to inhibit the Importantly, in this model with minimal glomerular
process at the level of the tubule and the interstitial changes, the glomerular filtration rate (GFR) was also
fibrogenic cell, the fibroblast, including maneuvers that markedly preserved in the relaxin-treated group, im-
interfere with the major fibrogenic cytokine produced by plying that reduction in interstitial fibrosis was responsi-
the tubular cell transforming growth factor-b1 (TGF-b1), ble for preservation of renal function.
or reduce the direct stimulatory effect of angiotensin on The mechanism by which relaxin attenuates this fibro-
the fibroblast by angiotensin-converting enzyme (ACE) sis is not clear. Garber et al [2] showed reduced immuno-
inhibitors or angiotensin receptor blockade [1]. histochemical staining for TGF-b1 and reduced cellular
In this issue of Kidney International, Garber et al [2] infiltration. At a cellular level, relaxin has previously
present experimental work suggesting that the hormone been shown to reduce collagen synthesis by dermal fi-
relaxin may also be an antifibrotic agent, acting at this broblasts [5], enhance the effects of interferon gamma
final common pathway of progressive renal failure. [8], inhibit TGF-b1 and interleukin-1 (IL-1)–induced col-
Relaxin was first described in 1926, when injections lagen expression [9], and increase secretion of collagen-
of serum from pregnant guinea pigs or rabbits were ase [4]. It has also been demonstrated that relaxin in-
shown to relax the interpubic ligament of female guinea creases nitric oxide production [3], with consequent
pigs [3]. Normally excreted into the bloodstream by the vasodilatory properties [10].
corpus luteum, decidua, and placenta, the hormone has Recombinant relaxin therapy currently has significant
since been demonstrated to have many important roles disadvantages, not the least of which is the requirement
in pregnancy, including not only softening effects on for continuous subcutaneous infusion [2, 6]. A better
connective tissue, but also reducing uterine contractility
understanding of the molecular and cellular interactions
and control of mammary gland growth and differentia-
responsible for the many effects of this polypeptide maytion [3].
lead to more practical analogues. In the meantime, appli-Structurally, relaxin is a multipolypeptide hormone of
cations clinically and experimentally will necessarily ad-about 6 kD with homology to insulin and insulin-like
dress fibrosing processes occurring over weeks not years.growth factors. Two molecular forms, designated H1 and
Accordingly, studies of clinically relevant experimentalH2, have been described, with H2 being the main form
models such as crescentic glomerulonephritis and ob-found in the bloodstream [3]. With the production of
structive nephropathy will be of great interest. In thisrecombinant H2 relaxin, clinical applications of this poly-
context, an initial report has suggested that relaxin im-peptide are being investigated.
proves both functional and structural outcomes in exper-The possibility of utilizing the antifibrotic effects clini-
imental anti-glomerular basement membrane nephritiscally has been the subject of speculation since studies in
(abstract; McDonald et al, J Am Soc Nephrol 10:576A,the late 1950s suggested that porcine relaxin induced
1999), with reduced serum creatinine and proteinuria astransient improvements in patients with scleroderma [3].
well as attenuated glomerular sclerosis and interstitial
fibrosis.
The universal biology of scarring indicates that strate-Ó 2001 by the International Society of Nephrology
1184
Editorial 1185
2. Garber SL, Mirochnik Y, Brecklin CS, et al: Relaxin decreasesgies to directly reduce fibrosis in the kidney will have
renal interstitial fibrosis and slows progression of renal disease.
implications for chronic fibrosing conditions in other or- Kidney Int 59:876–882, 2000
3. Bani D: Relaxin: A pleiotropic hormone. Gen Pharmac. 28:13–22,gans, although the long-term consequences of inhibiting
1997growth factor activity and collagen metabolism are un- 4. Unemori EN, Pickford LB, Salles AL, et al: Relaxin induces an
known, particularly with respect of normal healing. extracellular matrix degrading phenotype in human lung fibroblasts
in vitro and inhibits lung fibrosis in a murine model in vivo. J ClinThe increasing ability to inhibit fibrosis, as evidenced
Invest 98:2739–2745, 1996by Garber et al [2], suggests that potential strategies are 5. Unemori EN, Beck LS, Lee WP, et al: Human relaxin decreases
collagen accumulation in vivo in two rodent models of fibrosis.within reach, at least in the more rapidly progressive
J Invest Dermatol 101:280–285, 1993diseases.
6. Seibold JR, Korn JH, Simms R: Recombinant human relaxin in the
treatment of scleroderma: A randomized, double-blind, placebo-
Gavin J. Becker and Tim D. Hewitson controlled trial. Ann Intern Med 132:871–879, 2000
Melbourne, Australia 7. Garber SL, Mirochnik Y, Desai SS, et al: Angiotensin-converting
enzyme inhibition reduces the effect of bromoethylamine-induced
papillary necrosis and renal fibrosis. J Am Soc Nephrol 9:1052–Correspondence to Professor Gavin Becker, M.D., Department of
1059, 1998Nephrology, The Royal Melbourne Hospital, Victoria, NSW 3050, Aus-
8. Unemori EN, Bauer EA, Amento EP: Relaxin alone and in con-tralia.
junction with interferon-gamma decreases collagen synthesis byE-mail: Gavin.Becker@mh.org.au
cultured human scleroderma fibroblasts. J Invest Dermatol 99:337–
342, 1992
9. Unemori EN, Amento EP: Relaxin modulates synthesis and secre-REFERENCES
tion of procollagenase and collagen by human dermal fibroblasts.
1. Becker GJ, Hewitson TD: The role of tubulointerstitial injury in J Biol Chem 265:10681–10685, 1990
chronic renal failure. Curr Opin Nephrol Hypertension 9:133–148, 10. Danielson LA, Sherwood OD, Conrad KP: Relaxin is a potent
2000 renal vasodilator in conscious rats. J Clin Invest 103:525–533, 1999
